Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16573788 | 0.89 | CCR2 (0.51) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL16573787 | 0.87 | CCR2 (0.49) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226471 | 0.86 | CCR2 (0.53) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL15325891 | 0.85 | CCR2 (0.44) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL18699975 | 0.82 | CCR2 (0.47) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226272 | 0.81 | CCR2 (0.67) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226456 | 0.80 | CCR2 (0.59) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226449 | 0.80 | CCR2 (0.60) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226257 | 0.80 | CCR2 (0.62) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226415 | 0.80 | CCR2 (0.64) | CCR2KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150532-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-06 | — | — | US | disclosed |
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (US) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | CCR2 1/4885CCR1 3/4885TMEM97 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.